This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mickley Huff, L. Articles by Lee, J.-S. Search for Related Content PubMed PubMed Citation Articles by Mickley Huff, L. Articles by Lee, J.-S.

Aberrant Transcription from an Unrelated Promoter Can Result in MDR-1 Expression following Drug Selection In vitro and in Relapsed Lymphoma Samples

¹ Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; ² Emory University, Atlanta, Georgia; and ³ College of Medicine, Gyeongsang National University, Chinju, South Korea

Requests for reprints: Tito Fojo, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg. 10, Rm. 13N 240 MSC 1903, Bethesda, MD 20892. Phone: 301-496-2631; Fax: 301-402-1608.

The development of drug resistance in the treatment of cancer remains a major problem. The hallmark of multidrug resistance is cross-resistance to multiple structurally unrelated compounds. The MDR-1 gene encoding P-glycoprotein mediates one of the most extensively studied mechanisms of drug resistance. Previous studies led to the proposal that two promoters control expression of the MDR-1 gene, and these were designated the upstream and downstream promoters. In the present article, we provide evidence that transcripts originating from the putative upstream promoter of MDR-1 are in fact aberrant transcripts whose expression is regulated by nearby genomic sequences that include a human endogenous retroviral long terminal repeat (LTR). Expression of this LTR occurs in all cells. We show that following drug selection, especially in cases where gene amplification has occurred, MDR-1 transcripts can begin near this retroviral LTR with transcription proceeding in the direction opposite of the usual LTR transcription. Because expression of these aberrant MDR-1 transcripts (AMT) is found primarily in drug-resistant cell lines, we conclude that the development of drug resistance or the attendant drug exposure might have a role in the activation of this phenomenon or the selection of cells expressing AMTs. Demonstration of similar aberrant transcripts in tumor samples obtained from patients with relapsed lymphoma suggests that this phenomenon may also occur clinically. (Cancer Res 2005; 65(24): 11694-703)

This article has been cited by other articles:

				L. M. Huff, J.-S. Lee, R. W. Robey, and T. Fojo Characterization of Gene Rearrangements Leading to Activation of MDR-1 J. Biol. Chem., December 1, 2006; 281(48): 36501 - 36509. [Abstract] [Full Text] [PDF]

				Y. Zong, S. Zhou, S. Fatima, and B. P. Sorrentino Expression of Mouse Abcg2 mRNA during Hematopoiesis Is Regulated by Alternative Use of Multiple Leader Exons and Promoters J. Biol. Chem., October 6, 2006; 281(40): 29625 - 29632. [Abstract] [Full Text] [PDF]